Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Metrics to compare | NXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXLPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −0.7x | −0.6x | |
PEG Ratio | 0.01 | −0.20 | 0.00 | |
Price / Book | 5.3x | 1.1x | 2.6x | |
Price / LTM Sales | 47.3x | 1.5x | 3.1x | |
Upside (Analyst Target) | - | 101.9% | 55.7% | |
Fair Value Upside | Unlock | 21.2% | 6.8% | Unlock |